Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months’ follow-up: an optical coherence tomography study
- 2 November 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Heart and Vessels
- Vol. 31 (2), 206-211
- https://doi.org/10.1007/s00380-014-0598-0
Abstract
Incomplete neointimal coverage and malapposed struts after stenting are associated with increased risk of stent thrombosis. We aimed to evaluate neointimal coverage early after Resolute zotarolimus-eluting stent (R-ZES) implantation using optical coherence tomography (OCT). A total of 20 patients with de novo native coronary lesions with R-ZES were enrolled. Among these patients, 20 stented lesions in 19 patients were evaluated at 1, 2, and 3 months after R-ZES implantation. The strut apposition and neointimal coverage were evaluated by OCT. Neointimal hyperplasia (NIH) thickness and percentage of covered struts and the proportion of incompletely apposed struts were measured at 1-mm intervals. The mean percentages of covered stent struts were over 85 % within 3 months (88.4 ± 6.3 % at 1 month, 95.5 ± 5.5 % at 2 months, 93.6 ± 3.5 % at 3 months). The percentages of incompletely apposed struts were not significantly different among the groups (4.4 ± 4.2 % at 1 month, 1.9 ± 1.9 % at 2 months, 3.1 ± 2.2 % at 3 months, p = 0.51). Mean NIH thickness (38.9 ± 8.1 μm at 1 month, 70.6 ± 18.8 μm at 2 months, 54.1 ± 5.9 at 3 months, p = 0.0016) was thickest in the 2 months group. Most of all OCT findings within 2 months demonstrated neointimal coverage with low signal intensity. The neointimal coverage of ZES-R was over 85 % within 3 months. These data may support shorter requirement of dual antiplatelet therapy duration with R-ZES.Keywords
This publication has 21 references indexed in Scilit:
- 4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New-Generation Drug-Eluting StentsJournal of the American College of Cardiology, 2014
- Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantationEuropean Heart Journal, 2014
- Two‐week interval optical coherence tomography: Imaging evidence on neointimal coverage completion after implantation of the endeavor zotarolimus‐eluting stentCatheterization and Cardiovascular Interventions, 2013
- Difference in neointimal coverage at chronic stage between bare metal stent and sirolimus-eluting stent evaluated at stent-strut level by optical coherence tomographyHeart and Vessels, 2013
- Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS)Heart and Vessels, 2013
- Comparison of Early Strut Coverage Between Zotarolimus- and Everolimus-Eluting Stents Using Optical Coherence TomographyThe American Journal of Cardiology, 2012
- Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trialEuropean Heart Journal, 2011
- Intriguing Peri-Strut Low-Intensity Area Detected by Optical Coherence Tomography After Coronary Stent DeploymentCirculation Journal, 2010
- Optical coherence tomography patterns of stent restenosisAmerican Heart Journal, 2009
- Development of a novel biocompatible polymer system for extended drug release in a next‐generation drug‐eluting stentJournal of Biomedical Materials Research Part A, 2007